Program
eculizumab
Also written as “Eculizumab”, “Eculizumab Injection” and “Soliris (eculizumab)”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Myasthenia Gravis · Neuromyelitis Optica · Guillain-Barre Syndrome, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 311 open or running | phase 4since Mar 23, 2009 | Jul 18, 2005 | Dec 7, 2026phase 3 · NCT06724809 |
| AO GENERIUM | 20 open or running | phase 3since Jul 3, 2020 | Jul 3, 2020 | none ahead |
| Samsung Bioepis | 20 open or running | phase 3since Aug 12, 2019 | Oct 24, 2018 | none ahead |
| Biocad | 10 open or running | phase 3since May 16, 2025 | May 16, 2025 | none ahead |
Also a collaborator on its studies: cmic-co-ltd-japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Jul 18, 2005.
- May 15, 2014Phase 3 study in Delayed Graft FunctionAstraZeneca · NCT02145182 · 288 enrolled · United States, Australia, Brazil and more
- Nov 22, 2014Phase 3 study in Myasthenia GravisAstraZeneca · NCT02301624 · 117 enrolled · United States, Argentina, Belgium and more
- Oct 24, 2018Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT03722329 · 240 enrolled · Germany
- Nov 26, 2018Phase 3 study in Myasthenia GravisAstraZeneca · NCT03759366 · 12 enrolled · United States, Japan
- Aug 12, 2019Phase 3 study in Hemoglobinuria, ParoxysmalSamsung Bioepis · NCT04058158 · 50 enrolled · India, Korea, Republic of, Malaysia and more
- Nov 5, 2019Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT04155424 · 5 enrolled · United States, Canada, Germany and more
- Mar 23, 2020Phase 4 study in Hemoglobinuria, ParoxysmalAstraZeneca · NCT04320602 · 18 enrolled · United Kingdom
- Jul 3, 2020AO GENERIUM's first study: phase 3 study in Hemoglobinuria, ParoxysmalNew to AO GENERIUMAO GENERIUM · NCT04463056 · 32 enrolled · Russian Federation
- Nov 30, 2020Phase 3 study in Hemoglobinuria, ParoxysmalAO GENERIUM · NCT04679103 · 50 enrolled · Russian Federation
- Feb 9, 2021Phase 3 study in Guillain-Barre SyndromeAstraZeneca · NCT04752566 · 57 enrolled · Japan
- May 17, 20232 phase 3 studiesAstraZeneca · NCT05876351, NCT05886244
- Nov 19, 2024Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT06724809 · 21 enrolled · China
- Dec 11, 2024Phase 3 study in Myasthenia GravisAstraZeneca · NCT06764160 · 15 enrolled · China
- May 16, 2025Biocad's first study: phase 3 study in Hemoglobinuria, ParoxysmalNew to BiocadBiocad · NCT06987864 · 24 enrolled · Russian Federation
Ahead
- Dec 7, 2026Primary completion: phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT06724809
TargetBeta
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06987864Hemoglobinuria, Paroxysmal · Russian Federation | 3 | Completed | Biocad | Nov 2, 2022 | 24 |
| NCT06764160Myasthenia Gravis · China | 3 | Completed | AstraZeneca | Dec 29, 2025 | 15 |
| NCT06724809Neuromyelitis Optica · China | 3 | Active, not recruiting | AstraZeneca | Dec 7, 2026 | 21 |
| NCT05886244Hemoglobinuria, Paroxysmal · China | 3 | Completed | AstraZeneca | Apr 14, 2025 | 25 |
| NCT05876351Atypical Hemolytic Uremic · China | 3 | Completed | AstraZeneca | May 7, 2025 | 25 |
| NCT04752566Guillain-Barre Syndrome · Japan | 3 | Completed | AstraZeneca | Aug 3, 2022 | 57 |
| NCT04679103Hemoglobinuria, Paroxysmal · Russian Federation | 3 | Completed | AO GENERIUM | Apr 20, 2020 | 50 |
| NCT04463056Hemoglobinuria, Paroxysmal · Russian Federation | 3 | Completed | AO GENERIUM | Oct 16, 2018 | 32 |
| NCT04320602Hemoglobinuria, Paroxysmal · United Kingdom | 4 | Completed | AstraZeneca | Dec 20, 2022 | 18 |
| NCT04155424Neuromyelitis Optica · United States, Canada, Germany and more | 3 | Terminated | AstraZeneca | Jul 31, 2023 | 5 |
| NCT04058158Hemoglobinuria, Paroxysmal · India, Korea, Republic of, Malaysia and more | 3 | Completed | Samsung Bioepis | Sep 21, 2021 | 50 |
| NCT03759366Myasthenia Gravis · United States, Japan | 3 | Completed | AstraZeneca | Jan 6, 2022 | 12 |
| NCT03722329Healthy · Germany | 1 | Completed | Samsung Bioepis | Mar 29, 2019 | 240 |
| NCT02301624Myasthenia Gravis · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Jan 15, 2019 | 117 |
| NCT02145182Delayed Graft Function · United States, Australia, Brazil and more | 3 | Completed | AstraZeneca | Nov 22, 2016 | 288 |
| NCT02003144Neuromyelitis Optica · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Jul 12, 2021 | 119 |
| NCT01997229Myasthenia Gravis · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Feb 2016 | 125 |
| NCT01892345Neuromyelitis Optica · United States, Argentina, Australia and more | 3 | Terminated | AstraZeneca | Jul 17, 2018 | 143 |
| NCT01757431Atypical Hemolytic Uremic Syndrome · Japan | 2 | Completed | AstraZeneca | Sep 24, 2013 | 2 |
| NCT01567085Stage V Chronic Kidney Disease · Australia, France, Italy and more | 2 | Completed | AstraZeneca | Jun 11, 2015 | 80 |
| NCT01410916Shiga-like Toxin-producing Escherichia Coli · Germany | 3 | Completed | AstraZeneca | Jan 2012 | 198 |
| NCT01399593Antibody Mediated Rejection · United States, Australia, France and more | 2 | Terminated | AstraZeneca | May 13, 2014 | 102 |
| NCT01194973Atypical Hemolytic Uremic Syndrome · United States, Belgium, France and more | 2 | Completed | AstraZeneca | Oct 2013 | 44 |
| NCT01193348Atypical Hemolytic Uremic Syndrome · United States, Australia, Belgium and more | 2 | Completed | AstraZeneca | Jan 2014 | 22 |
| NCT01194804Hemoglobinuria, Paroxysmal | 2 | Completed | AstraZeneca | Sep 2010 | 27 |
| NCT01192399Hemoglobinuria, Paroxysmal | 2 | Completed | AstraZeneca | Jun 2008 | 29 |
| NCT00867932Hemoglobinuria, Paroxysmal · United States | 4 | Completed | AstraZeneca | May 12, 2011 | 7 |
| NCT00844844Atypical Hemolytic Uremic Syndrome · United States, Austria, France and more | 2 | Completed | AstraZeneca | Sep 2010 | 1 |
| NCT00844545Atypical Hemolytic Uremic Syndrome · United States, Austria, France and more | 2 | Completed | AstraZeneca | Sep 2010 | 16 |
| NCT00844428Atypical Hemolytic Uremic Syndrome · Canada, France, Germany and more | 2 | Completed | AstraZeneca | Oct 2010 | 5 |
| NCT00838513Atypical Hemolytic Uremic Syndrome · Canada, France, Germany and more | 2 | Completed | AstraZeneca | Oct 2010 | 15 |
| NCT00727194Myasthenia Gravis · United States, Canada, United Kingdom | 2 | Terminated | AstraZeneca | Mar 2011 | 14 |
| NCT00485576Allergic Asthma · Canada | 2 | Completed | AstraZeneca | Sep 2008 | 21 |
| NCT00122317Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Sep 2008 | 187 |
| NCT00122304Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | 85 | |
| NCT00122330Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | 75 |
How it is read
Names in the registry
- “Eculizumab”, 23 entries
- “eculizumab”, 10 entries
- “Eculizumab Injection”, 1 entry
- “Soliris (eculizumab)”, 1 entry
- “Elizaria®”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 14 studies
- Atypical Hemolytic Uremic Syndrome, 7 studies
- Myasthenia Gravis, 5 studies
- Neuromyelitis Optica, 4 studies
- Guillain-Barre Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.